Baseline characteristics of patients with MDS
| Characteristic . | No autoimmune disease . | Autoimmune disease . | P value . |
|---|---|---|---|
| 12 785 (84%) . | 2442 (16%) . | ||
| Age group, y, n (%) | <.001 | ||
| 65-70 | 237 (1.9%) | 51 (2.1%) | |
| 70-75 | 1382 (10.8%) | 306 (12.5%) | |
| 75-80 | 2963 (23.2%) | 627 (25.7%) | |
| >80 | 8203 (64.1%) | 1458 (59.7%) | |
| Female sex, n (%) | 5705 (44.6%) | 1331 (54.5%) | <.001 |
| Race/ethnicity∗ , n (%) | .013 | ||
| Non-Hispanic White | 11 027 (86.3%) | 2164 (88.6%) | |
| Non-Hispanic Black | 679 (5.3%) | 113 (4.6%) | |
| Hispanic | 216 (1.7%) | 37 (1.5%) | |
| Other† | 863 (6.8%) | 128 (5.2%) | |
| Rural residence, n (%) | 1779 (14%) | 299 (12%) | .027 |
| CCI, n (%) | <.001 | ||
| 0-1 | 6375 (49.9%) | 785 (32.2%) | |
| 2-4 | 4700 (36.7%) | 1094 (44.8%) | |
| >4 | 1710 (13.4%) | 563 (23%) | |
| Morphology subtype, n (%) | .192 | ||
| Refractory anemia | 1008 (7.9%) | 233 (9.5%) | |
| Refractory anemia with ring sideroblasts | 877 (6.9%) | 128 (5.2%) | |
| Refractory cytopenia with multilineage dysplasia | 842 (6.6%) | 165 (6.8%) | |
| MDS with isolated deletion del(5q) | 417 (3.3%) | 101 (4.1%) | |
| MDS, unclassifiable | 8061 (63%) | 1512 (61.9%) | |
| Refractory anemia with excess blasts | 1566 (12.2%) | 299 (12.3%) | |
| Refractory anemia with excess blasts in transformation | 14 (0.1%) | 4 (0.2%) | |
| MDS histologic risk, n (%) | .99 | ||
| Low | 1885 (14.7%) | 361 (14.8%) | |
| Intermediate | 9320 (72.9%) | 1778 (72.8%) | |
| High | 1580 (12.4%) | 303 (12.4%) | |
| Transfusion dependence, n (%) | |||
| Any product | 3600 (28.2%) | 798 (32.7%) | <.001 |
| Red blood cells | 3008 (23.5%) | 640 (26.2%) | .004 |
| Platelets | 592 (4.6%) | 158 (6.5%) | .001 |
| HMA treatment (≥4 cycles) | |||
| Azacitidine | 1542 (12%) | 292 (12%) | .165 |
| Decitabine | 582 (4.5%) | 105 (4.3%) | .241 |
| Either agent | 2124 (16.5) | 397 (16.3%) | .178 |
| HSCT, n (%) | 29 (0.2%) | 2 (0.08%) | .145 |
| Characteristic . | No autoimmune disease . | Autoimmune disease . | P value . |
|---|---|---|---|
| 12 785 (84%) . | 2442 (16%) . | ||
| Age group, y, n (%) | <.001 | ||
| 65-70 | 237 (1.9%) | 51 (2.1%) | |
| 70-75 | 1382 (10.8%) | 306 (12.5%) | |
| 75-80 | 2963 (23.2%) | 627 (25.7%) | |
| >80 | 8203 (64.1%) | 1458 (59.7%) | |
| Female sex, n (%) | 5705 (44.6%) | 1331 (54.5%) | <.001 |
| Race/ethnicity∗ , n (%) | .013 | ||
| Non-Hispanic White | 11 027 (86.3%) | 2164 (88.6%) | |
| Non-Hispanic Black | 679 (5.3%) | 113 (4.6%) | |
| Hispanic | 216 (1.7%) | 37 (1.5%) | |
| Other† | 863 (6.8%) | 128 (5.2%) | |
| Rural residence, n (%) | 1779 (14%) | 299 (12%) | .027 |
| CCI, n (%) | <.001 | ||
| 0-1 | 6375 (49.9%) | 785 (32.2%) | |
| 2-4 | 4700 (36.7%) | 1094 (44.8%) | |
| >4 | 1710 (13.4%) | 563 (23%) | |
| Morphology subtype, n (%) | .192 | ||
| Refractory anemia | 1008 (7.9%) | 233 (9.5%) | |
| Refractory anemia with ring sideroblasts | 877 (6.9%) | 128 (5.2%) | |
| Refractory cytopenia with multilineage dysplasia | 842 (6.6%) | 165 (6.8%) | |
| MDS with isolated deletion del(5q) | 417 (3.3%) | 101 (4.1%) | |
| MDS, unclassifiable | 8061 (63%) | 1512 (61.9%) | |
| Refractory anemia with excess blasts | 1566 (12.2%) | 299 (12.3%) | |
| Refractory anemia with excess blasts in transformation | 14 (0.1%) | 4 (0.2%) | |
| MDS histologic risk, n (%) | .99 | ||
| Low | 1885 (14.7%) | 361 (14.8%) | |
| Intermediate | 9320 (72.9%) | 1778 (72.8%) | |
| High | 1580 (12.4%) | 303 (12.4%) | |
| Transfusion dependence, n (%) | |||
| Any product | 3600 (28.2%) | 798 (32.7%) | <.001 |
| Red blood cells | 3008 (23.5%) | 640 (26.2%) | .004 |
| Platelets | 592 (4.6%) | 158 (6.5%) | .001 |
| HMA treatment (≥4 cycles) | |||
| Azacitidine | 1542 (12%) | 292 (12%) | .165 |
| Decitabine | 582 (4.5%) | 105 (4.3%) | .241 |
| Either agent | 2124 (16.5) | 397 (16.3%) | .178 |
| HSCT, n (%) | 29 (0.2%) | 2 (0.08%) | .145 |